-
1
-
-
0030966136
-
Soluble adhesion molecules and endothelial cell damage in HIV infected patients
-
1:CAS:528:DyaK2sXislOjs7g%3D 9134636
-
M Seigneur J Constans A Blann, et al. 1997 Soluble adhesion molecules and endothelial cell damage in HIV infected patients Thromb Haemost 77 646 1:CAS:528:DyaK2sXislOjs7g%3D 9134636
-
(1997)
Thromb Haemost
, vol.77
, pp. 646
-
-
Seigneur, M.1
Constans, J.2
Blann, A.3
-
3
-
-
0031902426
-
Plasma hypercoagulability is correlated to plasma HIV load
-
1:CAS:528:DyaK1cXkslWmsbc%3D 9684818
-
M Karmochkine A Ankri V Calvez, et al. 1998 Plasma hypercoagulability is correlated to plasma HIV load Thromb Haemost 80 208 1:CAS:528:DyaK1cXkslWmsbc%3D 9684818
-
(1998)
Thromb Haemost
, vol.80
, pp. 208
-
-
Karmochkine, M.1
Ankri, A.2
Calvez, V.3
-
4
-
-
70249090072
-
Preclinical atherosclerosis due to HIV infection: Carotid intima-medial thickness measurements from the FRAM study
-
10.1097/QAD.0b013e32832d3b85 19455012
-
C Grunfeld JA Delaney C Wanke, et al. 2009 Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study AIDS 23 1841 10.1097/QAD.0b013e32832d3b85 19455012
-
(2009)
AIDS
, vol.23
, pp. 1841
-
-
Grunfeld, C.1
Delaney, J.A.2
Wanke, C.3
-
5
-
-
52249121996
-
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men
-
10.1097/QAD.0b013e328300581d 18670221
-
RC Kaplan LA Kingsley SJ Gange, et al. 2008 Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men AIDS 22 1615 10.1097/QAD.0b013e328300581d 18670221
-
(2008)
AIDS
, vol.22
, pp. 1615
-
-
Kaplan, R.C.1
Kingsley, L.A.2
Gange, S.J.3
-
6
-
-
67651065515
-
Association of C-Reactive Protein and HIV Infection with Acute Myocardial Infarction
-
1:CAS:528:DC%2BD1MXns1ertb8%3D 10.1097/QAI.0b013e3181a9992c 19387353
-
VA Triant JB Meigs SK Grinspoon 2009 Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction J Acquir Immune Defic Syndr 51 268 1:CAS:528:DC%2BD1MXns1ertb8%3D 10.1097/QAI.0b013e3181a9992c 19387353
-
(2009)
J Acquir Immune Defic Syndr
, vol.51
, pp. 268
-
-
Triant, V.A.1
Meigs, J.B.2
Grinspoon, S.K.3
-
7
-
-
58149384809
-
-
2991 0929-8673/08 © 2008 Bentham Scie nce Publishers Ltd.
-
F. De Lorenzo, S. Collot-Teixeira, et al. Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures Current Medicinal Chemistry, 2008, 15, 2991-2999 2991 0929-8673/08 © 2008 Bentham Scie nce Publishers Ltd.
-
(2008)
Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures Current Medicinal Chemistry
, vol.15
, pp. 2991-2999
-
-
De Lorenzo, F.1
Collot-Teixeira, S.2
-
8
-
-
63149119125
-
HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction
-
10.1097/QAD.0b013e328325a87c 19177019
-
D Francisci S Giannini F Baldelli, et al. 2009 HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction AIDS 23 589 10.1097/QAD.0b013e328325a87c 19177019
-
(2009)
AIDS
, vol.23
, pp. 589
-
-
Francisci, D.1
Giannini, S.2
Baldelli, F.3
-
9
-
-
47649098334
-
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS:executive summary
-
This is an excellent discussion of relevant articles reviewing the state of the science on this subject
-
•• Grinspoon, SK, Grunfeld, C, Kotler, DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS:executive summary. Circulation 2008; 118:198). This is an excellent discussion of relevant articles reviewing the state of the science on this subject.
-
(2008)
Circulation
, vol.118
, pp. 198
-
-
Grinspoon, S.K.1
Grunfeld, C.2
Kotler, D.P.3
-
10
-
-
33847073815
-
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population
-
Mondy, K.; Overton, E.T.; Grubb, J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clinical Infections Dis., 2007, 44, 726-34.
-
(2007)
Clinical Infections Dis.
, vol.44
, pp. 726-734
-
-
Mondy, K.1
Overton, E.T.2
Grubb, J.3
-
11
-
-
77953747966
-
Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults
-
10.1089/met.2009.0094 20235745
-
CR Pullinger BE Aouizerat C Gay, et al. 2010 Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults Metab Syndr Relat Disord. 8 3 279 86 10.1089/met.2009.0094 20235745
-
(2010)
Metab Syndr Relat Disord.
, vol.8
, Issue.3
, pp. 279-86
-
-
Pullinger, C.R.1
Aouizerat, B.E.2
Gay, C.3
-
12
-
-
0037032941
-
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial
-
DOI 10.1097/00002030-200212060-00010
-
V Joly P Flandre V Meiffredy, et al. 2002 Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial AIDS 16 2447 1:CAS:528:DC%2BD38XptFKgu7s%3D 10.1097/00002030-200212060-00010 12461419 (Pubitemid 35471693)
-
(2002)
AIDS
, vol.16
, Issue.18
, pp. 2447-2454
-
-
Joly, V.1
Flandre, P.2
Meiffredy, V.3
Leturque, N.4
Harel, M.5
Aboulker, J.-P.6
Yeni, P.7
-
13
-
-
33750227103
-
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy
-
DOI 10.1097/01.aids.0000247574.33998.03, PII 0000203020061024000006
-
GJ Moyle CA Sabin J Cartledge, et al. 2006 A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy AIDS 20 2043 1:CAS:528:DC%2BD28XhtV2rsrnE 10.1097/01.aids. 0000247574.33998.03 17053350 (Pubitemid 44611057)
-
(2006)
AIDS
, vol.20
, Issue.16
, pp. 2043-2050
-
-
Moyle, G.J.1
Sabin, C.A.2
Cartledge, J.3
Johnson, M.4
Wilkins, E.5
Churchill, D.6
Hay, P.7
Fakoya, A.8
Murphy, M.9
Scullard, G.10
Leen, C.11
Reilly, G.12
-
14
-
-
2442593038
-
In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3 T3 and human preadipocytes or adipocytes
-
Apr 9 Epub 2004 Jan 13
-
El Hadri K, Glorian M, Monsempes C, Dieudonné MN, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3 T3 and human preadipocytes or adipocytes. Chem. 2004 Apr 9;279(15):15130-41. Epub 2004 Jan 13.
-
(2004)
Chem
, vol.279
, Issue.15
, pp. 15130-15141
-
-
El Hadri, K.G.1
-
15
-
-
33845417218
-
-
Jan Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study
-
Biol Res Nurs. 2007 Jan;8(3):177-85. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. Robinson FP, Quinn LT, Rimmer JH.
-
(2007)
Biol Res Nurs.
, vol.8
, Issue.3
, pp. 177-185
-
-
Robinson, F.P.1
Quinn, L.T.2
Rimmer, J.H.3
-
16
-
-
2342589533
-
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study
-
DOI 10.1097/00002030-200404300-00011
-
A Martin DE Smith A Carr, et al. 2004 Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study AIDS 18 1029 1:CAS:528:DC%2BD2cXkvFKhsr8%3D 10.1097/00002030-200404300-00011 15096806 (Pubitemid 38591194)
-
(2004)
AIDS
, vol.18
, Issue.7
, pp. 1029-1036
-
-
Martin, A.1
Smith, D.E.2
Carr, A.3
Ringland, C.4
Amin, J.5
Emery, S.6
Hoy, J.7
Workman, C.8
Doong, N.9
Freund, J.10
Cooper, D.A.11
-
17
-
-
1642456562
-
Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study
-
DOI 10.1086/380790
-
GA McComsey DJ Ward SM Hessenthaler, et al. 2004 Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study Clin Infect Dis 38 263 1:CAS:528:DC%2BD2cXhtFSgu74%3D 10.1086/380790 14699460 (Pubitemid 38113036)
-
(2004)
Clinical Infectious Diseases
, vol.38
, Issue.2
, pp. 263-270
-
-
McComsey, G.A.1
Ward, D.J.2
Hessenthaler, S.M.3
Sension, M.G.4
Shalit, P.5
Lonergan, J.T.6
Fisher, R.L.7
Williams, V.C.8
Hernandez, J.E.9
-
18
-
-
43649093166
-
Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication
-
Apr Epub 2008 Jan 20
-
Amet T, Nonaka M, Dewan MZ, et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008 Apr;10(5):471-80. Epub 2008 Jan 20.
-
(2008)
Microbes Infect
, vol.10
, Issue.5
, pp. 471-480
-
-
Amet, T.1
Nonaka, M.2
Dewan, M.Z.3
-
19
-
-
0042832397
-
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
-
DOI 10.1086/378131
-
MP Dube JH Stein JA Aberg, et al. 2003 Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clin Infect Dis 37 613 10.1086/378131 12942391 (Pubitemid 37100800)
-
(2003)
Clinical Infectious Diseases
, vol.37
, Issue.5
, pp. 613-627
-
-
Dube, M.P.1
Stein, J.H.2
Aberg, J.A.3
Fichtenbaum, C.J.4
Gerber, J.G.5
Tashima, K.T.6
Henry, W.K.7
Currier, J.S.8
Sprecher, D.9
Glesby, M.J.10
-
20
-
-
0141612021
-
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams
-
1:CAS:528:DC%2BD3sXnvVSht7o%3D 10.1016/S0002-9149(03)00779-3 12948873
-
HB Brewer Jr 2003 Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams Am J Cardiol 92 23K 1:CAS:528:DC%2BD3sXnvVSht7o%3D 10.1016/S0002-9149(03)00779-3 12948873
-
(2003)
Am J Cardiol
, vol.92
-
-
Brewer Jr., H.B.1
-
21
-
-
40549128295
-
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Results of ACTG A5186
-
DOI 10.1097/QAI.0b013e31815bace2
-
JG Gerber DW Kitch CJ Fichtenbaum, et al. 2008 Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186 J Acquir Immune Defic Syndr 47 459 1:CAS:528:DC%2BD1cXjtVemurs%3D 10.1097/QAI.0b013e31815bace2 17971707 (Pubitemid 351366958)
-
(2008)
Journal of Acquired Immune Deficiency Syndromes
, vol.47
, Issue.4
, pp. 459-466
-
-
Gerber, J.G.1
Kitch, D.W.2
Fichtenbaum, C.J.3
Zackin, R.A.4
Charles, S.5
Hogg, E.6
Acosta, E.P.7
Connick, E.8
Wohl, D.9
Kojic, E.M.10
Benson, C.A.11
Aberg, J.A.12
-
23
-
-
51749084593
-
Treatment of altered body composition in HIV-associated lipodystrophy: Comparison of rosiglitazone, pravastatin, and recombinant human growth hormone
-
Jul-Aug
-
Macallan DC, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials. 2008 Jul-Aug; 9(4):254-68.
-
(2008)
HIV Clin Trials
, vol.9
, Issue.4
, pp. 254-268
-
-
MacAllan, D.C.1
Baldwin, C.2
Mandalia, S.3
-
24
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
1:CAS:528:DC%2BD2sXms1SisrY%3D 10.1056/NEJMoa072761 17517853
-
SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 1:CAS:528:DC%2BD2sXms1SisrY%3D 10.1056/NEJMoa072761 17517853
-
(2007)
N Engl J Med
, vol.356
, pp. 2457
-
-
Nissen, S.E.1
Wolski, K.2
-
25
-
-
34249896151
-
Use of thiazolidinediones in HIV-infected patients: What have we learned?
-
DOI 10.1086/518008
-
S Grinspoon 2007 Use of Thiazolidinediones in HIV-Infected Patients: What Have We Learned? J Infect Dis 195 1731 1:CAS:528:DC%2BD2sXnt1Gksb0%3D 10.1086/518008 17492586 (Pubitemid 46870243)
-
(2007)
Journal of Infectious Diseases
, vol.195
, Issue.12
, pp. 1731-1733
-
-
Grinspoon, S.1
-
26
-
-
56749131189
-
Effect of rosiglitazone on peroxisome proliferatoractivated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
-
1:CAS:528:DC%2BD1MXhtFSltbY%3D 10.1086/593179 18954260
-
PW Mallon R Sedwell G Rogers, et al. 2008 Effect of rosiglitazone on peroxisome proliferatoractivated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction J Infect Dis 198 1794 1:CAS:528:DC%2BD1MXhtFSltbY%3D 10.1086/593179 18954260
-
(2008)
J Infect Dis
, vol.198
, pp. 1794
-
-
Mallon, P.W.1
Sedwell, R.2
Rogers, G.3
-
27
-
-
42149084966
-
Effect of pioglitazone on HIV-1-related lipodystrophy: A randomized double-blind placebo-controlled trial (ANRS 113)
-
1:CAS:528:DC%2BD1cXksVegsb0%3D 18389900
-
L Slama E Lanoy MA Valantin, et al. 2008 Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113) Antivir Ther 13 67 1:CAS:528:DC%2BD1cXksVegsb0%3D 18389900
-
(2008)
Antivir Ther
, vol.13
, pp. 67
-
-
Slama, L.1
Lanoy, E.2
Valantin, M.A.3
-
28
-
-
77953707169
-
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: A meta-analysis of randomized trials
-
10.1186/1471-2334-10-183 20573187
-
SH Sheth RJ Larson 2010 The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials BMC Infect Dis. 10 183 10.1186/1471-2334-10-183 20573187
-
(2010)
BMC Infect Dis.
, vol.10
, pp. 183
-
-
Sheth, S.H.1
Larson, R.J.2
-
29
-
-
77950800360
-
Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism
-
Apr Epub 2009 Dec 8
-
Hansen BR, Haugaard SB, Jensen FK, et al. Long-term high-physiological- dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med. 2010 Apr;11(4):266-75. Epub 2009 Dec 8.
-
(2010)
HIV Med.
, vol.11
, Issue.4
, pp. 266-275
-
-
Hansen, B.R.1
Haugaard, S.B.2
Jensen, F.K.3
-
30
-
-
77649226509
-
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension
-
1:CAS:528:DC%2BC3cXisFejur4%3D 10.1097/QAI.0b013e3181cbdaff 20101189
-
J Falutz D Potvin JC Mamputu, et al. 2010 Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension J Acquir Immune Defic Syndr. 53 3 311 22 1:CAS:528:DC%2BC3cXisFejur4%3D 10.1097/QAI.0b013e3181cbdaff 20101189
-
(2010)
J Acquir Immune Defic Syndr.
, vol.53
, Issue.3
, pp. 311-22
-
-
Falutz, J.1
Potvin, D.2
Mamputu, J.C.3
-
31
-
-
67449093468
-
Expert Tesamorelin, a human growth hormone releasing factor analogue
-
1:CAS:528:DC%2BD1MXitlWrtrs%3D 10.1517/13543780802707658
-
Y Wang B Tomlinson 2009 Expert Tesamorelin, a human growth hormone releasing factor analogue Opin Investig Drugs. 18 3 303 10 1:CAS:528: DC%2BD1MXitlWrtrs%3D 10.1517/13543780802707658
-
(2009)
Opin Investig Drugs.
, vol.18
, Issue.3
, pp. 303-10
-
-
Wang, Y.1
Tomlinson, B.2
-
32
-
-
58149273826
-
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
-
1:CAS:528:DC%2BD1cXhtVekt73F 10.1097/QAD.0b013e32830a5058 18690162
-
J Falutz S Allas JC Mamputu, et al. 2008 Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation AIDS. 22 14 1719 28 1:CAS:528:DC%2BD1cXhtVekt73F 10.1097/QAD.0b013e32830a5058 18690162
-
(2008)
AIDS
, vol.22
, Issue.14
, pp. 1719-28
-
-
Falutz, J.1
Allas, S.2
Mamputu, J.C.3
-
33
-
-
0026566740
-
Endothelial cell dysfunction in HIV infection
-
1:STN:280:DyaK387it1SqtQ%3D%3D 1531074
-
A Lafeuillade MC Alessi I Poizot-Martin, et al. 1992 Endothelial cell dysfunction in HIV infection J Acquir Immune Defic Syndr. 5 2 127 31 1:STN:280:DyaK387it1SqtQ%3D%3D 1531074
-
(1992)
J Acquir Immune Defic Syndr.
, vol.5
, Issue.2
, pp. 127-31
-
-
Lafeuillade, A.1
Alessi, M.C.2
Poizot-Martin, I.3
-
34
-
-
70350118312
-
Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients
-
S Ferraro S Paolillo M Gargiulo, et al. 2009 Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients G Ital Cardiol (Rome). 10 9 596 601
-
(2009)
G Ital Cardiol (Rome).
, vol.10
, Issue.9
, pp. 596-601
-
-
Ferraro, S.1
Paolillo, S.2
Gargiulo, M.3
-
35
-
-
79551547470
-
-
September 1 Untreated HIV Infection and Large and Small Artery ElasticityJason V. Baker, MD, MS, † Daniel Duprez, MD, PhD,† Joshua Rapkin, MS,‡ Katherine Huppler Hullsiek, PhD,‡ Harrison Quick, BS,‡ Richard Grimm, MD, PhD, James D. Neaton, PhD, and Keith Henry, MD
-
J Acquir Immune Defic Syndr. 2009 September 1; 52(1): 25-31. Untreated HIV Infection and Large and Small Artery ElasticityJason V. Baker, MD, MS, † Daniel Duprez, MD, PhD,† Joshua Rapkin, MS,‡ Katherine Huppler Hullsiek, PhD,‡ Harrison Quick, BS,‡ Richard Grimm, MD, PhD, James D. Neaton, PhD, and Keith Henry, MD
-
(2009)
J Acquir Immune Defic Syndr
, vol.52
, Issue.1
, pp. 25-31
-
-
|